The effect of bosentan, a dual receptor antagonist, on DUs prevention and healing was evaluated in two high-quality RCTs (RAndomized, double-blind, Placebo controlled study with bosentan on healing and prevention of Ischemic Digital ulcers in patients with systemic Sclerosis (RAPIDS)-1 and RAPIDS-2) including altogether 310 patients with SSc with a history of or at least one active DU at baseline.